

Development of Orally Available Small-Molecule Hit and Lead Compounds for Immuno-Oncology via Inhibition of the CD73-Adenosine Axis and Enhancement of Antitumor Immune Activation

Gwangju Institute of Science and Technology



ONCOLOGY		Hit
Product Type	Small molecules	
Indication	Immune checkpoint inhibitor-resistant cancers	
Target	CD73	
MoA(Mechanism of Action)	• Suppression of extracellular adenosine production and immunosuppressive adenosine accumulation in the TME • Reduction of adenosine-mediated receptor signaling • Restoration of CD8⁺ T cell and NK cell cytotoxic functions, leading to reduced tumor immune evasion	
Competitiveness	• Non-nucleotide CD73 inhibitors with improved oral delivery potential • Differentiation from hematologic malignancy-focused CD73 inhibitors toward solid tumor indications	
Development Stage	Hit	
Route of Administration	oral administration (intended)	

Any unauthorized distribution or reproduction of this material is strictly prohibited.